Plus Therapeutics Inc (NAS:PSTV)
$ 1.16 0.08 (7.41%) Market Cap: 6.37 Mil Enterprise Value: 4.98 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Plus Therapeutics Inc at ThinkEquity Conference Transcript

Oct 26, 2022 / 07:00PM GMT
Release Date Price: $6.67 (-2.22%)
Nick Christian
ThinkEquity

Everyone, thank you all for coming. My name is Nick Christian. I'm with ThinkEquity. And our next presenting company is Plus Therapeutics. So I'll turn it over to them.

Marc Hedrick
Plus Therapeutics, Inc. - President & CEO

Thanks a lot, Nick. How's the auditory? All good?

Yeah, my name is Marc Hedrick. I'm the President, CEO of Plus Therapeutics. So just a little bit of an overview of the company. We're a Texas-based targeted radiotherapeutic company, developing treatments for some of the worst cancers on the planet, different kinds of brain cancer and metastatic and inoperable liver cancer.

One unique aspect about the company is we've been able to obtain funding for our lead programs through Phase 2, both from the NIH in the state of Texas. The state of Texas is actually the second largest funder of cancer research in the world behind the NIH. We just received almost a $20 million grant from CPRIT, which is the funding agency in Texas.

So, as I mentioned, we're going after some of the toughest,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot